Data analytics, knowledge management and Artificial Intelligence (AI) have experienced explosive growth trends over the past decade. Integrated platforms have been implemented to increase drug candidate efficacy and safety throughout the preclinical research.
Our platforms consist of proprietary hardware, biological, molecular and digital technologies. We are looking forward to partnering with large pharmaceutical companies and co-developing drug R&D projects.
Artificial Intelligence Drug Discovery (AIDD) platform, aimed at accelerating the drug development process. The automated machine-learning platform covers all the main stages of early drug discovery: CD ComputaBio can now officially provide valuable solutions to the pharmaceutical industry via our proprietary AIDD platform.
Computer aided drug design (CADD) platform, aimed at accelerating the drug development process. CADD has become a powerful technique to facilitate the drug design process thereby minimizing time and costs. CD ComputaBio can also provide efficient solutions to the pharmaceutical industry via our proprietary CADD platform.
Genetics and Biochemistry Phenotypic Screen
High Throughput Screen or Other Screening Formats
Hit Validation by Co-crystallization and Binding Assays
Medicinal Chemistry Optimization
Potency, ADME and Toxicity
Tech Trends in Artificial Intelligence What's up, what's down, what lies ahead, only found in MedAI!